# Evaluate the Safety and Efficacy of Calcitonin Gene-Related Peptide (CGRP) Antagonists in Patients With Dry Eye Disease and Asthenopia

> **NCT05895500** · — · COMPLETED · sponsor: **Nvision Laser Eye Centers** · enrollment: 103 (actual)

## Conditions studied

- Dry Eye
- Asthenopia

## Interventions

- **DRUG:** Injection for SC administration (120mg/syringe)
- **DRUG:** Tablet (50mg/tablet), oral

## Key facts

- **NCT ID:** NCT05895500
- **Lead sponsor:** Nvision Laser Eye Centers
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-10
- **Primary completion:** 2023-11-09
- **Final completion:** 2023-11-09
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2024-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05895500

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05895500, "Evaluate the Safety and Efficacy of Calcitonin Gene-Related Peptide (CGRP) Antagonists in Patients With Dry Eye Disease and Asthenopia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05895500. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*